Through our operating subsidiary, National Stem Cell, we have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Our initial focus in stem cell therapeutics is to achieve a leadership position in:
Expansion Technology:
Proteonomix is developing a unique growth medium that allows expansion far beyond the traditional 10:1 achieved in conventional methods before cellular replication errors make it nonviable. This technology is of benefit to any treatment or process that might be improved by drastically increased concentrations or numbers of cells.
Cryopreservation:
Proteonomix is developing an innovative cryopreservation technique resulting in substantial reduction in lost cells during the freezing and thawing process. This technology is of benefit where it is advantageous to store cellular material for later use, to maintain stock, or to perform long distance transportation.
Anti-Inflammatory:
Proteonomix's StromaCel™ cellular materials has given some indications as a general anti-inflammatory. We are looking for partners wishing to explore this indication for conditions other than myocardial infarction.
Technology
Cell Growth Media
We recognize the impact on society that the scarcity of transplant grade umbilical cord blood stem cells imposes; unmet transplantation increases morbidity and mortality. Your company intends to capitalize on this need by creating new stem cell expansion and cryopreservation techniques.
Expansion Technology:
